Sept 26 (Reuters) – Under fire generic drugmaker Mylan NV
reiterated it makes a net profit of $104, after taxes,
for a pair of its EpiPen emergency allergy treatment sold in the
United States, the…
The post Mylan reiterates profit on EpiPen two-pack in US appeared first on NASDAQ.